Safety and Efficacy of Secukinumab in Mild Psoriasis (NCT03131570) | Clinical Trial Compass
CompletedPhase 2
Safety and Efficacy of Secukinumab in Mild Psoriasis
United States23 participantsStarted 2017-05-23
Plain-language summary
Mild psoriasis not only progresses to moderate-to-severe psoriasis but also precedes systemic inflammation that leads to psoriatic arthritis and cardiovascular comorbidities. By curing mild psoriasis with a short-term anti- interleukin (IL)-17A treatment, investigators may reduce the costs of treating psoriasis and associated medical conditions, including psoriatic arthritis, cardiovascular disease, and diabetes.
Who can participate
Age range18 Years
SexALL
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Inclusion criteria
✓. Written informed consent must be obtained before any assessment is performed
✓. 18 years of age or older
✓. Chronic plaque-type psoriasis for at least 6 months
✓. Negative PPD (negative chest w-ray if positive) or negative QuantiFERON-TB Gold
✓. Have a PASI between 6 and 12 and Body Surface Area (BSA) affected by plaque-type psoriasis less than 10% at screening and baseline
✓. Willing to wash off steroid creams and ultraviolet B light (UVB) therapy for 2 weeks prior to the baseline visit
Exclusion criteria
✕. Has a nonplaque form of psoriasis (eg, erythrodermic, guttate, or pustular)
✕. Has previously received Secukinumab or other biologics
✕. History of Inflammatory Bowel Disease (IBD)
✕. History of Rheumatoid Arthritis
✕. Use of topical treatments for psoriasis, including steroids, vitamin D derivatives, vitamin A derivatives, salicylic acid, tar (except moisturizers) and/or ultraviolet A light (UVA)/UVB phototherapy within the last 2 weeks (if these have used them, the participant needs to wash off of them for at least 2 weeks after signing consent prior to baseline)
✕. Is pregnant, nursing, or planning a pregnancy (both men and women) within 5 months following the last administration of study drug
What they're measuring
1
Percentage of Subjects Who Have 75% or More Reduction in [Psoriasis Area-and-severity Index Score (PASI)] (PASI75)